

side effects. This measure also preserves any immune-related research data taken in the first week postflight. Your crew tolerates their first dose of mRNA vaccine with no complications, followed by the second dose at the recommended timeframe, completing their initial series of vaccination against SARS-CoV-2.

Chough N, Thompson M, Johansen B. *Aerospace medicine clinic: spaceflight immunology and ethics*. *Aerosp Med Hum Perform*. 2023;94(8):645–647.

ACKNOWLEDGMENTS

The authors would like to thank Dr. Tina Bayuse and the Johnson Space Center Pharmacy team, as well as Drs. Brian Crucian, Robert Haddon, and Kathleen McMonigal, for their professional advice and feedback, and Dr. Gene Dowell for his sage independent review. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of UTMB, KBR, or NASA.

REFERENCES

- Center for Disease Control. Moderna COVID-19 vaccine: temperature log for frozen vaccine storage. 2021.
- Chough NG, Stepaniak P, McMonigal K, Barratt MB, Lindgren K et al. Operational considerations for death in space: historical background, aspects, and risks of spaceflight. Paper presented at: Aerospace Medical Association Annual Scientific Meeting; August 29–September 23, 2021; Denver, CO. *Aerosp Med Hum Perform*. 2021; 92(6):468.
- Crucian B, Stowe RP, Mehta S, Quiriarte H, Pierson D, Sams C. Alterations in adaptive immunity persist during long-duration spaceflight. *NPJ Microgravity*. 2015; 1(1):15013.
- Du B, Daniels VR, Vaksman Z, Boyd JL, Crady C, Putcha L. Evaluation of physical and chemical changes in pharmaceuticals flown on space missions. *AAPS J*. 2011; 13(2):299–308.
- Federal Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers) Emergency Use Authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). 2019. [Accessed February 21, 2023]. Available from <https://www.fda.gov/media/144637/download>.
- Gridley DS, Slater JM, Luo-Owen X, Rizvi A, Chapes SK et al. Spaceflight effects on T lymphocyte distribution, function and gene expression. *J Appl Physiol*. 2009; 106(1):194–202.
- Makedonas G, Mehta SK, Scheuring RA, Haddon R, Crucian BE. SARS-CoV-2 pandemic impacts on NASA ground operations to protect ISS astronauts. *J Allergy Clin Immunol Pract*. 2020; 8(10):3247–3250.
- Mehta SK, Laudenslager ML, Stowe RP, Crucian BE, Feiveson AH et al. Latent virus reactivation in astronauts on the International Space Station. *NPJ Microgravity*. 2017; 3(1):11.
- Varkey B. Principles of clinical ethics and their application to practice. *Med Princ Pract*. 2021; 30(1):17–28.
- FAQs on use of COVID-19 vaccines by pilots and air traffic controllers. 2022. [Accesses February 21, 2023]. Available from https://www.faa.gov/coronavirus/guidance_resources/vaccine_faq.

Erratum

Mayes RS, Keirns CJ, Hicks AG, Menner LD, Lee MS, Wagner JH, Baltzer RL. *USAFSAM Aeromedical Consultation Service Medical Risk Assessment and Airworthiness Matrix*. *Aerosp Med Hum Perform*. 2023; 94(7):514–522.

DOI: <https://doi.org/10.3357/AMHP.6154.2023>

In the above article, the authors missed errors in the Methods section, p. 517, left-hand column, first full paragraph, eighth sentence and in the equations about two-thirds of the way down the page. The sentence in question says “For instance, an “occasional” event would occur once every 10,000 (10^{-4}) to 100,000 (10^{-5}) h.” It should read “...an “occasional” event would occur once every 10,000 (10^4) to 100,000 (10^5) h.” In the equations, the denominators show as, respectively, 10^{-5} and 10^{-4} (see highlight in the equation below).

$$1 - \left[1 - \left(\frac{1}{10^{-5}} \right) \right]^{365.25 \times 24} = 0.0839$$

$$1 - \left[1 - \left(\frac{1}{10^{-4}} \right) \right]^{365.25 \times 24} = 0.5838$$

These are incorrect. The denominators should simply be 10^5 and 10^4 , respectively. The authors apologize for these mistakes.